Ilaris 150 MG/ML vialml
Ended Awarded
- Contract number
- SPE2DB26FX1KW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,828
Award facts
- Contract value 100% obligated
- $12,827.51 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,827.51 to DMS Pharmaceutical Group Inc. for ILARIS 150 MG/ML vials, a specialty pharmaceutical product. This firm fixed-price delivery order, issued on November 3, 2025, with an ultimate completion date of November 25, 2025, represents a single transaction under DMS Pharmaceutical Group's broader prime vendor contract with the DLA. The award utilized no set-aside designation, allowing the woman-owned small business to compete on an unrestricted basis. Performance will occur at the contractor's headquarters in Park Ridge, Illinois.
DMS Pharmaceutical Group Inc., a woman-owned pharmaceutical wholesaler established since 2001, holds a single-award Indefinite Delivery Contract (IDC) under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, with a ceiling value of $499,999,999 and completion through December 31, 2036. This $30.3 billion governmentwide acquisition strategy contract positions DMS Pharmaceutical Group as a critical supplier of branded and generic prescription medications, biologics, vaccines, and medical consumables to support Department of Defense healthcare operations globally. The current delivery order for ILARIS exemplifies the company's role in fulfilling specialized pharmaceutical requirements across the military medical system, with the contractor operating as the sole awardee under its prime vendor agreement and maintaining no identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DB26FX1KW?
SPE2DB26FX1KW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DB26FX1KW worth?
The government has obligated $12,828 on SPE2DB26FX1KW.
Is contract SPE2DB26FX1KW an order under another contract?
Yes. SPE2DB26FX1KW is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1KW competed?
The extent of competition for SPE2DB26FX1KW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award